J. Raats

发表

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

M. Casey, S. Stein, C. Geyer, 2008, Breast Cancer Research and Treatment.

Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.

Chih-Hsin Yang, F. de Marinis, J. Wolf, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL).

J. Vansteenkiste, F. Blackhall, J. Raats, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.

M. Ghielmini, S. Rondeau, G. Martinelli, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer.

J. Raats, G. Falkson, H. Falkson, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen

P. Ruff, J. Raats, L. Burgess, 2009, Cancer Chemotherapy and Pharmacology.

Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial.

M. Ghielmini, S. Rondeau, T. Pabst, 2020, Blood advances.

Prognostic significance of the neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small-cell lung cancer

J. Raats, A. Theron, Jacqueline M. Hall, 2020, Lung cancer management.

Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer.

L. Paz-Ares, A. Szczesna, J. Schiller, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 study of combination therapy with liposomal doxorubicin and carboplatin in patients with relapsed, platinum sensitive ovarian cancer.

J. Raats, B. Rapoport, G. Cohen, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fadrozole hydrochloride, a new nontoxic aromatase inhibitor for the treatment of patients with metastatic breast cancer

J. Raats, G. Falkson, H. Falkson, 1992, The Journal of Steroid Biochemistry and Molecular Biology.

Suramin in combination with mitomycin C in hormone-resistant prostate cancer. A phase II clinical study.

J. Raats, B. Rapoport, G. Falkson, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Survival determinants in patients with advanced ovarian cancer.

S. Ansell, J. Raats, B. Rapoport, 1993, Gynecologic oncology.

179 A phase II second line study of liposomal doxorubicin and carboplatin in patients with recurrent ovarian cancer with a disease free interval equal or greater than 6 months

J. Raats, B. Rapoport, G. Cohen, 2003 .

9004 Vandetanib plus pemetrexed vs pemetrexed as 2nd-line therapy in patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

J. Vansteenkiste, F. Blackhall, J. Raats, 2009 .